BRIEF- Basilea Pharmaceutica announces isavuconazole received QIDP designation from FDA

July 16 Thu Jul 17, 2014 3:37am EDT

Related Topics

July 16(Reuters) - Basilea Pharmaceutica AG :

* Says U.S. Food and Drug Administration designated

Isavuconazole as Qualified Infectious Disease Product (QIDP) for oral and intravenous treatment of invasive candidiasis Source text for Eikon: Further company coverage:

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.